Vmn2r20 Inhibitors
Vmn2r20 inhibitors pertain to a class of chemical agents designed to selectively bind to and inhibit the function of a specific type of receptor known as Vmn2r20. This receptor is part of a larger family of Vomeronasal type-2 receptors (V2Rs), which are G protein-coupled receptors (GPCRs) predominantly found in the vomeronasal organ (VNO) of certain mammals. Vmn2r20 receptors are implicated in the detection of pheromonal signals, chemical compounds that play a crucial role in intra-species communication. By inhibiting Vmn2r20, these inhibitors affect the receptor's natural function, potentially altering the signal transduction pathways that normally follow the receptor's activation. The chemical structure of Vmn2r20 inhibitors is designed to fit the binding site of the Vmn2r20 receptor with high affinity and specificity, thereby preventing the receptor's normal ligands from associating and initiating a biological response.
The development and study of Vmn2r20 inhibitors involve intricate chemical synthesis and biochemical characterization to ensure that these molecules achieve their intended inhibitory effect without affecting other receptor types. Structurally, these inhibitors may vary widely, encompassing small molecules, peptides, or other complex organic compounds. The interaction between Vmn2r20 inhibitors and their target receptor is often elucidated through various analytical techniques, such as ligand-binding assays, structure-activity relationship studies, and computational modeling, which help to refine their molecular properties. The specificity of Vmn2r20 inhibitors is paramount, as off-target effects can lead to unintended consequences due to the broad nature of GPCR functions throughout the mammalian body. Advances in the understanding of the Vmn2r20 receptor's structure and function have been instrumental in guiding the design of these inhibitors, with a focus on achieving optimal binding characteristics and receptor selectivity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Capsaicin | 404-86-4 | sc-3577 sc-3577C sc-3577D sc-3577A | 50 mg 250 mg 500 mg 1 g | $96.00 $160.00 $240.00 $405.00 | 26 | |
Capsaicin targets the vanilloid receptor subtype 1 (TRPV1), which is involved in sensory perception. By activating TRPV1, capsaicin can desensitize sensory neurons and reduce the perception of stimuli that would otherwise be recognized by receptors such as Vmn2r20. | ||||||
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $79.00 $104.00 $166.00 $354.00 $572.00 | 1 | |
Quinine is known to block ion channels and inhibit their signaling. As Vmn2r20 is a receptor that may be involved in signal transduction, quinine's blockade of ion channels could indirectly inhibit the signaling pathway in which Vmn2r20 is involved. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $51.00 $131.00 | ||
Lidocaine acts as a sodium channel blocker, which can inhibit action potentials in neurons. If Vmn2r20 is involved in neuronal signaling, lidocaine's action could decrease the functional activity of Vmn2r20 by preventing neuron firing. | ||||||
Reserpine | 50-55-5 | sc-203370 sc-203370A | 1 g 5 g | $137.00 $414.00 | 1 | |
Reserpine irreversibly blocks the vesicular monoamine transporter, which can lead to depletion of monoamine neurotransmitters. If Vmn2r20's activity is modulated by monoamine levels, reserpine could indirectly lessen its functional activity. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a beta-blocker that can inhibit adrenergic signaling. Since Vmn2r20 may play a role in adrenergic pathways, propranolol could indirectly inhibit Vmn2r20 by dampening the downstream effects of adrenergic receptor activation. | ||||||
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | $208.00 | 2 | |
CNQX is an AMPA/kainate receptor antagonist that can inhibit excitatory neurotransmission. If Vmn2r20 is implicated in glutamatergic signaling, CNQX would indirectly inhibit its function by reducing excitatory neurotransmission. | ||||||
(±)-Baclofen | 1134-47-0 | sc-200464 sc-200464A | 1 g 5 g | $56.00 $258.00 | ||
Baclofen is a GABA_B receptor agonist that inhibits neurotransmission. If Vmn2r20 is involved in pathways that are negatively regulated by GABAergic signaling, then baclofen could reduce the activity of Vmn2r20 by enhancing inhibitory neurotransmission. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Diltiazem is a calcium channel blocker which could inhibit the influx of calcium. If Vmn2r20's function is dependent on calcium signaling, diltiazem could indirectly inhibit Vmn2r20 by preventing calcium-dependent processes. | ||||||
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
Ouabain is a specific inhibitor of the Na⁺/K⁺-ATPase pump, which could disrupt ion gradients critical for neuronal activity. If Vmn2r20 is part of neuronal signaling pathways, ouabain could diminish its activity by altering ion homeostasis. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol is a dopamine receptor antagonist that can alter dopaminergic signaling. If Vmn2r20 is modulated by dopamine levels, haloperidol could indirectly inhibit its function by blocking dopamine receptors. | ||||||